April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
The Effect of Baseline Aqueous Humor Dynamics on the Ocular Hypotensive Efficacy of Latanoprost or Timolol
Author Affiliations & Notes
  • V. Gulati
    Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska
  • C. B. Toris
    Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska
  • D. A. Ghate
    Ophthalmology, University of Mississippi Medical Center, Jackson, Mississippi
  • C. B. Camras
    Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska
  • Footnotes
    Commercial Relationships  V. Gulati, None; C.B. Toris, None; D.A. Ghate, None; C.B. Camras, None.
  • Footnotes
    Support  Allergan Horizon Grant, RPB
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2034. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      V. Gulati, C. B. Toris, D. A. Ghate, C. B. Camras; The Effect of Baseline Aqueous Humor Dynamics on the Ocular Hypotensive Efficacy of Latanoprost or Timolol. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2034.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Latanoprost(LP) and timolol are two of the most effective and commonly-used drugs in glaucoma therapy. They reduce intraocular pressure (IOP) by different mechanisms. LP improves aqueous humor outflow and timolol reduces aqueous flow. We sought to determine whether baseline aqueous humor dynamics influenced the ocular hypotensive efficacy of either drug.

Methods: : This is a retrospective investigation of data from 30 ocular hypertensive subjects in a previous, double-masked crossover fluorophotometric study. IOP (9 AM and 11:30 AM) was determined by pneumatonometry, aqueous flow and outflow facility (C) by fluorophotometry and uveoscleral outflow (Fu) by mathematical calculation using the Goldmann equation and an episcleral venous pressure of 11 mmHg. Measurements were made at baseline and at 1 and 6 weeks of treatment with timolol 0.5% twice daily or LP 0.005% once daily in the evening. Scatter plots were evaluated and linear correlations were computed where appropriate, with and without correction for baseline IOP.

Results: : At baseline, significant (p<0.05) correlations included: 1) higher IOP and lower C (r=-0.47); 2) higher IOP and higher Fu (r=0.39). The percent IOP reduction produced by LP or timolol after 1 or 6 weeks of treatment was significantly (p<0.0001) correlated with the baseline IOP (r= 0.62 to 0.66). The percent drop in IOP with LP at 1 or 6 weeks significantly (p=0.001 and p=0.032, respectively) correlated with baseline Fu (r=0.63 and r=0.42) and at 1 week significantly (p=0.007) inversely correlated with baseline C (r=-0.51). At 1 or 6 weeks, the percent IOP reductions produced by LP were significantly (p=0.001) correlated with the rise in C (r=0.62 and r=0.38). Using a multivariate analysis, the correlations between IOP reduction and either C or Fu (with a single exception) became insignificant after correcting for the confounding variable of baseline IOP. Only the positive correlation between IOP reduction and increase in C at 1 week remained significant for LP in the multivariate analysis. The ocular hypotensive efficacy of timolol did not correlate with the baseline or change in aqueous flow at either 1 or 6 weeks.

Conclusions: : Patients with higher baseline IOPs respond better to LP or timolol than patients with lower baseline IOPs. The ocular hypotensive efficacy of timolol is not affected by baseline aqueous flow. The ocular hypotensive efficacy of LP correlated with change in C only at 1 week. No conclusion can be made concerning effects of LP or timolol on Fu as the results are inconsistent.

Keywords: aqueous • outflow: trabecular meshwork • trabecular meshwork 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×